http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0182984-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 1985-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1992-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0182984-B1 |
| titleOfInvention | Use of fully synthetic alpha-human atrial natriuretic peptide (alpha-hanap) |
| abstract | Fully synthetic alpha-human atrial natriuretic peptide (alpha-hANaP) in a highly purified injectable or infusible form is useful for treating cardiac insufficiency, more specifically with oedematosis and sodium retention, oliguric renal failure, blood pressure disregulation and ascites in chronic liver diseases, vasopressin disregulation, posterior pituitary malfunction, and the psychotropic effects induced thereby. |
| priorityDate | 1984-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.